WINTON GROUP Ltd Raises Stock Holdings in Dynavax Technologies Corporation $DVAX

WINTON GROUP Ltd boosted its position in Dynavax Technologies Corporation (NASDAQ:DVAX) by 93.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 111,187 shares of the biopharmaceutical company’s stock after purchasing an additional 53,607 shares during the quarter. WINTON GROUP Ltd owned approximately 0.09% of Dynavax Technologies worth $1,104,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. Hantz Financial Services Inc. increased its stake in shares of Dynavax Technologies by 236.9% in the 3rd quarter. Hantz Financial Services Inc. now owns 3,854 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 2,710 shares in the last quarter. LSV Asset Management bought a new position in shares of Dynavax Technologies during the third quarter valued at approximately $89,000. Osaic Holdings Inc. increased its stake in shares of Dynavax Technologies by 15.1% during the second quarter. Osaic Holdings Inc. now owns 9,336 shares of the biopharmaceutical company’s stock valued at $93,000 after purchasing an additional 1,226 shares in the last quarter. Summit Global Investments purchased a new position in shares of Dynavax Technologies during the third quarter valued at approximately $113,000. Finally, Catalyst Funds Management Pty Ltd bought a new stake in shares of Dynavax Technologies in the 2nd quarter worth approximately $121,000. Institutional investors own 96.96% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Weiss Ratings restated a “sell (d)” rating on shares of Dynavax Technologies in a research note on Wednesday, January 21st. Wall Street Zen raised Dynavax Technologies to a “strong-buy” rating in a report on Saturday, February 14th. Finally, William Blair cut Dynavax Technologies from an “outperform” rating to a “hold” rating in a research note on Wednesday, December 24th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average target price of $21.00.

Dynavax Technologies Price Performance

Shares of NASDAQ:DVAX opened at $15.50 on Thursday. The business has a 50-day simple moving average of $15.51 and a two-hundred day simple moving average of $12.41. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.94 and a current ratio of 7.62. The firm has a market cap of $1.82 billion, a price-to-earnings ratio of -41.89 and a beta of 0.97. Dynavax Technologies Corporation has a fifty-two week low of $9.20 and a fifty-two week high of $15.73.

Insider Buying and Selling

In other news, COO David F. Novack sold 114,000 shares of the stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $15.64, for a total transaction of $1,782,960.00. Following the transaction, the chief operating officer directly owned 63,344 shares of the company’s stock, valued at $990,700.16. This represents a 64.28% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 2.98% of the company’s stock.

About Dynavax Technologies

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.